AGARWALEYEDr. Agarwal's Health Care Ltd.
Dr. Agarwal's Health Care's Amar Agarwal to become Executive Chairman
- Management change
- eye care services
Reviewed byKeshav SehgalBlacklitt Research
Dr. Agarwal's Health Care (NSE: AGARWALEYE) has appointed and re-designated Dr. Amar Agarwal, its Chairman and Non-Executive Director, as Executive Chairman (Whole-Time Director) for three years, it said in a filing on 05 Nov 2026. The change follows the effectiveness of the amalgamation with Dr. Agarwal's Eye Hospital Limited.
The appointment and its terms
The Board approved the appointment and re-designation at its meeting on 05 Nov 2026. The term runs for three years, from 01 Nov 2026 to 31 Oct 2029. The company says the appointment is consequent to the effectiveness of the Scheme of Amalgamation between Dr. Agarwal's Eye Hospital Limited and the company.
The company says Dr. Amar Agarwal was Chairman and Managing Director of Dr. Agarwal's Eye Hospital Limited, the erstwhile material subsidiary, and that his continued engagement as Executive Chairman would help retain and enhance the reputation and quality of eye care practices. He is aged 66, has been on the Board since the company's inception, and has over 40 years of experience in eye care.
The terms and remuneration are said to be identical to those he already drew at Dr. Agarwal's Eye Hospital Limited. They are subject to approval by members, to be sought through a postal ballot under Section 110 of the Companies Act, 2013. The company will inform the exchanges about the ballot's dispatch, cut-off and e-voting period in due course.
Family ties on the board
The filing states that Dr. Amar Agarwal is the father of Dr. Adil Agarwal, Whole-Time Director and Chief Executive Officer, and Dr. Anosh Agarwal, Chief Operating Officer. The company's latest quarter, Q1 FY27, showed consolidated total income of ₹620.43 crore, up 23.9% year on year, and net profit of ₹55.02 crore, up 44.6%.
What the appointment means for Dr. Agarwal's Health Care's shareholders
The change alters the executive role of the Chairman and adds a three-year term that members have yet to approve. The filing does not state the remuneration amount, what the Chairman role will now carry, or who holds the Chairman's post after re-designation.
The next dated step is the postal ballot, whose dispatch date and e-voting period the company has not yet set.
At a glance
| Item | Detail |
|---|---|
| Person | Dr. Amar Agarwal (DIN 00435684) |
| Role | Executive Chairman (Whole-Time Director) |
| Effective | 01 Nov 2026 |
| Term | Three years, to 31 Oct 2029 |
| Approval | Postal ballot of members, notice approved by the Board |
Filed with NSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.